Navigating Treatment Failure in CML

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 09, 2015
Expiration Date: October 09, 2016

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Patients with chronic myelogenous leukemia (CML) who are treated with first-generation TKIs have a 90% chance of surviving for at least five years following initiation of treatment. Nevertheless, a significant number of CML patients experience treatment failure, which is associated with increased risk of disease progression and reduced survival. This interactive case study will use a decision-tree format to explore several critical aspects of CML management that can contribute to treatment failure. By making clinical decisions as the case progresses from diagnosis to treatment and monitoring, learners will gain a greater understanding of approaches that may be used to reduce the risk of treatment failure in CML and to support improved outcomes in these patients.

Target Audience

This activity is designed for community hematologists/oncologists and other relevant multidisciplinary clinicians who provide care to patients with CML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe monitoring strategies and regimens that will measure assessment of response in CML, focusing on how the results of this monitoring should be utilized to determine when a change in therapy is required
  • Identify alternative therapies that can be incorporated into treatment regimens when a CML patient fails to respond adequately to TKI therapy and an adjustment in the treatment plan is required
  • Outline treatment options in CP-CML for patients with resistant mutations, including second- and third-generation TKIs, focusing on those patients with the T315I “gatekeeper” mutation

Agenda

Navigating Treatment Failure in CML – Stuart L. Goldberg, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 09, 2016. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Stuart L. Goldberg, MD
Division of Leukemia
John Theurer Cancer Center
Hackensack, New Jersey

Dr. Stuart Goldberg received his medical degree from Pennsylvania State University, Milton S. Hershey Medical Center. He completed his internal medicine residency and his hematology-oncology fellowship at George Washington University Medical Center. He also completed a bone marrow transplantation fellowship at Fred Hutchinson Cancer Research Center. Dr. Goldberg is a part of the Division of Leukemia, John Theurer Cancer Center in Hackensack, New Jersey.

Dr. Goldberg specializes in medical oncology and leukemia, and is board certified in medical oncology, hematology and internal medicine. He is a member of the American College of Physicians, American Society of Blood and Marrow Transplantation, American Society of Hematology, American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Southwest Oncology Group, and the Myelodysplastic Foundation, among others. Dr. Goldberg specializes in treating all types of leukemia and myelodysplastic syndromes with a variety of treatment modalities, including chemotherapy and stem cell transplantation.

Accreditation

CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-051-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Stuart Goldberg has received honoraria related to formal advisory activities from Pfizer Inc. and Novartis; the development of educational materials and consultant fees from Novartis; as well as speakers’ bureau activities from Bristol-Myers Squibb Company and Novartis. He has received grant support related to research activities from Bristol-Myers Squibb, Novartis, and Pfizer.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Goldberg has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Goldberg has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingcml.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.
MediCom Worldwide, Inc. acknowledges the collaborative support from The Leukemia & Lymphoma Society.

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.